MacuLogix marks 1 million dark adaptation tests

Article

The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.

MacuLogix marks 1 million dark adaptation tests

MacuLogix, Inc. announced Wednesday that more than 1 million dark adaptation tests have been performed using its device technology.

MacuLogix’s technology allows for eye care professionals (ECPs) to detect, monitor, and treat age-related macular degeneration (AMD) 3 years before clinical diagnosis.

This includes the original AdaptDx and the head-mounted AdaptDx Pro guided by Theia, both of which use the same priority technology to measure dark adaptation speed, according to a news release.

Impaired dark adaptation is the earliest biomarker of AMD, according to Julie Rodman, OD, MS, FAAO, a professor at NOVA Southeastern University.

“Often manifested as night vision problems, this functional impairment becomes apparent years before drusen are visible,” Rodman said in a news release. “In fact, many optometrists are now testing dark adaptation for every patient over age 50 as part of their standard of care.”


MacuLogix Co-founder and Chief Technology Officer Gregory R. Jackson, PhD, FAAO, said that over the past several years, the standard of care in AMD has risen due to primary eye care’s more diligent approach to preventing avoidable vision loss.

“Each of these 1 million tests is symbolic of a swift and sizable shift toward a new normal in AMD management,” he said, in a statement.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Dr. Julie Rodman previews her SECO presentations
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.
© 2025 MJH Life Sciences

All rights reserved.